(Adds details on study and next steps in paragraphs 2-4)
Jan 6 (Reuters) - Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
Shares of the drug developer were down 6.6% in extended trade following the announcement.
The study's main goal was to demonstrate a change in disease severity over time and increase survival, comparing DNL343 to a placebo, as measured by a specific scale.
"We remain deeply committed to fully understanding the effects of DNL343 in ALS and will further evaluate the data before determining next steps", said Merit Cudkowicz, the study's principal investigator.
A more comprehensive analysis of the study results will become available later in 2025, according to Carole Ho, the company's medical chief.
(Reporting by Puyaan Singh in Bengaluru; Editing by Tasim Zahid)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。